Efficacy and safety of Netarsudil in primary angle closure glaucoma.
Phase 4
- Conditions
- Health Condition 1: H401- Open-angle glaucoma
- Registration Number
- CTRI/2023/08/056186
- Lead Sponsor
- Maharaja agrasen medical college
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Inclusion Criteria:
1. Patients of either sex of age > 40 years.
2. Clinically diagnosed patients of:
Primary angle closure glaucoma
3. Able to give informed consent and follow study instructions
Exclusion Criteria
Exclusion Criteria:
1 Patients having known hypersensitivity to any component of the formulation.
2 Previous glaucoma surgery or refractive surgery.
3 Report of ocular injury in either eye.
4 Inability to come for regular follow up.
5 Ocular diseases with inflammation as a manifestation.
6 Use of systemic medication (steroids) that could affect the IOP.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of Intra Ocular Pressure from baseline.Timepoint: Reduction of Intra Ocular Pressure from baseline at 15 days, 1 month 2 months and 3 months.
- Secondary Outcome Measures
Name Time Method To report the proportion of adverse drug reaction by using naranjo scale.Timepoint: 15 days, 1 month, 2 months, 3 months & 6 months after drug administration